Get the Stockscreener App
2.41
0.62%
-0.015
Pavmed Inc stock is traded at $2.41, with a volume of 12,563.
It is down -0.62% in the last 24 hours and down -38.52% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$2.425
Open:
$2.425
24h Volume:
12,563
Relative Volume:
1.18
Market Cap:
$19.27M
Revenue:
$85,000
Net Income/Loss:
$-22.16M
P/E Ratio:
-0.064
EPS:
-37.672
Net Cash Flow:
$-6.29M
1W Performance:
-13.62%
1M Performance:
-38.52%
6M Performance:
-73.55%
1Y Performance:
-83.72%
1-Day Range:
$2.39
$2.50
1-Week Range:
$2.22
$2.81
52-Week Range:
$2.22
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
2.41 | 19.27M | 85,000 | -22.16M | -6.29M | -37.67 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
PAVmed Launches New At-the-Market Equity Offering - The Globe and Mail
PAVmed Launches New At-the-Market Equity Offering - TipRanks
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Q1 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Inc. Series Z Warrant (PAVMZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
PAVmed Inc (PAVMW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Completion of Louisville VA Medical Center delayed until 2027 - AOL.com
PAVmed (PAVM) Results Check: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Stock Move: Shares Finish 1.57% Up at the ClosePost-Earnings Reaction - vinanet.vn
WVU PCH updates their signage and navigation - AOL.com
VA touts psilocybin trial for vets, but relief could take time - AOL.com
Verasonics Appoints New Senior Vice President, Research & Development - AOL.com
PAVmed (PAVM) Results Check: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Stock Move: Shares Finish 1.57% Up at the CloseInvestor Earnings Call - dars.gov.et
PAVmed (PAVM) Report Card: The Available Earnings Metric Delivers a Miss at the Close; Post-Earnings Trading: The Stock Loses 4.98% in the Current UpdateProfitability Analysis - vinanet.vn
Former President of DePuy Synthes U.S. Joins Peptilogics Board - AOL.com
PAVmed (PAVM) Report Card: The Available Earnings Metric Delivers a Miss at the Close; Post-Earnings Trading: The Stock Loses 4.98% in the Current UpdateProfit Guidance Range - dars.gov.et
PAVmed Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-08-17 - Seeking Alpha
St. Joseph's Health Now Offers Pluvicto For Advanced Prostate Cancer - AOL.com
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
PAVmed reports Q2 progress with Veris, Lucid, a... - Pluang
PAVmed (PAVM) Q2 2026 Earnings Call Transcript - The Globe and Mail
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
Pavmed Stock Price Forecast. Should You Buy PAVM? - StockInvest.us
PAVM Q1 2026 Earnings: EPS of -$4.42 Misses Consensus by 519%; Shares Rally 9.7%ROA Comparison - vinanet.vn
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVM Q2 FY2026 earnings call - finance.biggo.com
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com India
PAVM Looks 288.7% Overvalued on GF Value™ - GuruFocus
Is PAVmed Inc (PAVM) Overvalued After Q2 Earnings Miss? EPS at -$0.55, Revenue at $0.05M; GF Score: 32/100 - GuruFocus
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Nigeria
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Australia
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com India
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Canada
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Australia
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Canada
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 revenue jumps to $33k; $30m warrants issued - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVM: Q2 saw operational progress, positive clinical results, and improved financial positioning - TradingView
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com
PAVM: Net loss narrowed and operational progress advanced, with regulatory milestones on track - TradingView
PAVmed Q2 2026 Earnings Call: Complete Transcript - Benzinga
Q2 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Finansavisen
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.41%
7.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):